Skip to main content
OpenTrials
Completed

NCT Number: NCT05503303

T1D, Metabolic Syndrome and Insulin Resistance

Patients with type 1 diabetes (T1D) and metabolic syndrome (MS) require high doses of insulin to achieve a glycemic control, due to insulin resistance (IR). The investigators identified the presence of metabolic syndrome and insulin resistance in patients with T1D in a population of southeast Mexico.

The sampled population was recruited from the Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez"; from August 2021 to February 2022, graduated physicians interviewed patients previously diagnosed with T1D. This study included patients older than 18 years and at least six months after being diagnosed with T1D. The interviewers excluded patients who did not attend regular consultations and those who did not agree to participate or to give a blood sample. A diabetologist evaluated and diagnosed all patients based on the World Health Organization (WHO) criteria.

Fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols were determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics. The reasearch team determined glycated hemoglobin concentrations by an enzymatic immunoassay method.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Isela Esther Juarez Rojop

Villahermosa, Tabasco, 86090, Mexico

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least six months after being diagnosed with T1D

Exclusion criteria

  • Did not attend regular consultations
  • Did not agree to participate or to give a blood sample

Treatment and study plan

Primary outcomes

  1. Glycated hemoglobin

    Time frame: March 2022

    Concentrations by an enzymatic immunoassay method

  2. Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols

    Time frame: March 2022

    Determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics

Sponsors and collaborators

Lead sponsor

Universidad Juárez Autónoma de Tabasco

Other

Registry information

Official study title

Clinical Characteristics in Adults With Type 1 Diabetes, Metabolic Syndrome and Insulin Resistance

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 16, 2022
Registry last updated
Aug 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.